Indications and timing of allogeneic bone marrow transplantation in myelodysplastic syndromes

Leukemia and Lymphoma

Volumn 27, Issue 5-6, 1997, Pages 475-485

  Sutton, Laurent ^a   Leblond, Véronique ^a   Ribaud, Patricia ^a   Jouet, Jean Pierre ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Allogeneic; Bone marrow transplantation; Myelodysplastic syndrome; Treatment decision

Indexed keywords

BUSULFAN; CYTARABINE; ETOPOSIDE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; HUMAN; MYELODYSPLASTIC SYNDROME; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT PLANNING;

EID: 0031444873     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709058314     Document Type: Article

References (55)

1. Koeffler, H. P., (1986). Myelodysplastic syndromes (Preleukemia). Semin. Haematol., 23, 284-299.
2. List, A. F., and Jacobs, A., (1992). Biology and pathogenesis of the myelodysplastic syndromes, Semin. Oncol., 19, 14-24.
3. Raza, A., Gezer, S., Mundle, S., et al. (1995). Apoptosis in bone marrow biopsy samples involving stromal and hematopoïetic cells in 50 patients with myelodysplastic syndromes. Blood, 86, 268-276.
4. Bennet, J. M., Catovsky, D., Daniel, M. T., et al. (1982). Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol., 51, 189-199.
5. Tricot, G., Boogaerts, M. A., De Wolf-Peeters, C., et al. (1985). The myelodysplastic syndromes : different evolution patterns based on sequential morphological and cytogenetic investigations. Br. J. Haematol., 59, 659-670.
6. Jacobs, A., (1991). Genetic lesions in preleukemia. Leukemia, 5, 277-282.
7. Coiffier, B., Adeleine, P., Viala, J. J., et al. (1983). Dysmyelopoietic syndromes. A search for prognostic factors in 193 patients. Cancer, 52, 83-90.
8. Foucar, K., Langdon, R. M., Armitage, J. O., et al. (1985). Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases. Cancer, 56, 553-561.
9. Kerkhofs, M., Hermans, J., Haak, H. L., and Lecksma, C. H. W., (1987). Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases, Br. J. Haematol., 65, 73-81.
10. Levine, E. G., and Bloomfiel, C. D., (1992). Leukemias and myelodysplastic syndromes secondary to drug, radiation and environmental exposure. Semin. Oncol., 19, 47-84.
11. Mufti, G. J., Stevens, J. R., Oscier, D. G., et al. (1985). Myelodysplastic syndromes: a scoring system of prognostic significance. Br. J. Haematol., 59, 425-433.
12. Worsley, A., Oscier, D. G., Stevens, J., et al. (1988). Prognostic features of chronic myelomonocytic leukemia: a modified Bournemouth score gives the best prediction of survival. Br. J. Haematol., 68, 17-21.
13. Sanz, G. F., Sanz, M. A., Vallespi, T., et al. (1989). Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood, 74, 395-408.
14. Aul, C., Gattermann, N., Heyll, A., et al. (1992). Primary myelodysplastic syndromes: Analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia, 6, 52-59.
15. Tricot, R., Vlietinck, R., Boogaerts, M. A., et al. (1985). Prognostic factors in the myelodysplastie syndromes: Importance of initial data on peripheral blood counts, hone marrow cytology, trephine biopsy and chromosomal analysis. Br. J. Haematol., 60, 19-32.
16. Morel, P., Hebbar, M., Lai, J. L., et al. (1993). Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can he incorporated in a new scoring system: a report of 408 cases. Leukemia, 7, 1315-1323.
17. Aul, C., and Schneider, W., (1989). The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes. Cancer, 64, 1812-1818
18. Koeffler, M. P., Heitjan, D., Mertelsmann, R., et al. (1988). Randomized study of 13-Cis retinoic acid v placebo in the myelodysplastic disorders. Blood, 71, 703-708.
19. Aul, C., Runde, V., and Gatterman, N., (1993). All-trans retinoic acid in patients with myelodysplastic syndromes: Results of a pilot study. Blood, 82, 2967-2974.
20. Holcombe, R. F., (1993). Mini dose interferon α-2a in the treatment of myelodysplasia. Leukemia, 7, 192-195.
21. Andreeff, M., Stone, R., Michaeli, J., et al. (1992). Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: A phase If clinical trial with a differentiation-inducing agent. Blood, 80, 2604-2609.
22. Silverman, L. R., Holland, J. F., Weinberg, R. S., et al (1993). Effects of treatment with 5-Asacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia, 7, 21-29.
23. Gradishar, W. J., Le Beau, M. M., O'Laughlin, R., et al. (1992). Clinical and cytogenetic responses to granulocyte-macrophage colony-stimulating factor in therapy-related myelodysplasia. Blood, 80, 2463-2470.
24. Ganser, A., Ottman, O. G., Seipelt, G., et al. (1993). Effect of long term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromes. Leukemia, 7, 696-701.
25. Hellström-Lindberg, (1995). Efficacy of erythropoietin in the myelodysplastic syndromes: A meta-analysis of 205 patients from 17 studies. Br. J. Haematol., 89, 67-71.
26. Gordon, M. S., Nemunaitis, J., Hoffman, R., et al. (1995). A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood, 85, 3066-3076.
27. Fenaux, P., Morel, P., Rose. C., et al. (1991). Prognostic factors in adult De Novo myelodysplastic syndromes treated by intensive chemotherapy. Br. J. Haematol., 77, 497-501.
28. Wattel, E., Solary, E., Caillot, D., et al. (1996). Prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Blood, 88 suppl 1, 130 (abstract).
29. Appelbaum, F. R., Storb, R., Ramberg. R. E., et al. (1987). Treatment of preleukemia syndromes with marrow transplantation. Blood, 69, 92-96.
30. O'Donnell, M. R., Nademanee, A. P., Synder, D. S., et al. (1987). Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J. Clin. Oncol., 5, 1822-1826.
31. Bélanger, R., Gyger, M., Perreault, C., et al (1988). Bone marrow transplantation for myelodysplastic syndromes. Br. J. Haematol., 69, 29-33.
32. Kolb, H. J., Holler, E., Bender-Götze, C., et al. (1989). Myeloablative conditioning for marrow transplantation in myelodysplastic syndromes and paroxysmal nocturnal haemoglobinuria. Bone Marrow Transplant., 4, 29-34.
33. Guinan, E. C., Tarbell, N. J., Tantravahi, R., and Weinstein, H. J., (1989). Bone marrow transplantation for children with myelodysplastic syndromes. Blood,13, 619-622.
34. Marmont, A. M., and Horowitz, M. M., (1990). Outcome of allogeneic bone marrow transplantation for myelodysplastic syndromes. Bone Marrow Transplant., 5 suppl 2, 71 (abstract).
35. De Witte, T., Zwaan, F., Hermans, J., et al. (1990). Allogeneic bone marrow transplantation for secondary leukemia and myelodysplastic syndrome: a survey by the leukaemia working party of the European Bone Marrow Transplantation Group (EBMTG). Br. J Haematol., 74, 151-155.
36. Appelbaum, F. R., Barrall, J., Storb, R., et al. (1990). Bone marrow transplantation for patients with myelodysplasia. Ann. Intern. Med., 112, 590-597.
37. Longmore, G., Guinan, E. C., Weinstein, H. J., et al. (1990). Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia. J. Clin, Oncol., 8, 1707-1714.
38. Sutton, L., Leblond, V., Le Maignan, C., et al. (1991). Bone marrow transplantation for myelodysplastic syndrome and secondary leukemia : outcome of 86 patients. Bone Marrow Transplant., 7 suppl 2, 39.
39. Nevill, T. J., Shepherd, J. D., Reece, D. E., et al. (1992). Treatment of myelodysplastic syndrome with busulfancyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant., 10, 445-450.
40. Ratanatharathorn, V., Karanes, C., Uberti, J., et al (1993). Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood, 81, 2194-2199.
41. Anderson, J. E., Appelbaum, F. R., Fisher, L. D., et al. (1993). Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome, Blood, 82, 677-681.
42. Anderson, J. E., Appelbaum, F. R., and Storb, R., (1995). An update on allogeneic marrow transplantation for myelodysplastic syndrome. Leuk. Lymph., 17, 95-99.
43. Anderson, J. E., Appelbaum, F. R., Schoch, G., et al. (1996). Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of Busulfan, Cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin. Oncol., 14, 220-226.
44. Anderson, J. E., Appelbaum, F. R., Schoch, G., et al. (1996). Allogeneic marrow transplantation for refractory anemia: A comparison of two preparative regimens and analysis of prognostic factors. Blood, 87, 51-58.
45. Nichols, K., Parsons, S. K., and Guinan, E., (1996). Long-term follow-up of 12 pediatric patients with primary myelodysplastic syndrome treated with HLA-identical sibling donor bone marrow transplantation. Blood, 87, 4020-4022.
46. Sutton, L., Chastang, C., Ribaud, P., et al. (1996). Factors influencing outcome in De Novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients. Blood, 88, 358-365.
47. Anderson, J. E., Anasetti, C., Appelbaum, F. R., et al. (1996). Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br. J. Haematol., 93, 59-67.
48. Ballen, K. K., Gillilaud ,D. G., Guinan, E. C., et al. (1995). Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Blood, 86 suppl 1, 95 (abstract).
49. Fung, H. C., Sheperd, J. D., Nautel, S. H., et al (1996). Allogeneic bone marrow transplantation for adults with primary myelodysplastic syndrome: Evaluation of prognostic factors. Blood, 88 suppl 1, 480 (abstract).
50. Runde, V., De Witte, T., Arnold, R., et al. (1995). Bone marrow transplantation from HLA-identical siblings as first line treatment in patients with myelodysplastic syndromes or secondary acute myelogenous leukemia: An european survey. Blood, 86 suppl 1, 96 (abstract).
51. Geller, R. B., Sarel, R., Piantadosi, S., et al. (1989). Allogeneic bone marrow transplantation after high dose busulfan and cyclophosphamide regimen. Blood, 73, 2209.
52. Tutschka, P. J., Capelan, E. A., and Klein, J. P., (1987). Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood, 70, 1382.
53. Kernan, N. A., Bartsch, G., Ash, R. C., et al. (1993). Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program. N. Engl. J. Med., 328, 593-602.
54. Clift, R. A., Buchner, C. D., Appelbaum. F. R., et al. (1991). Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens. Blood. 77, 1660-1665.
55. Lynch, M. H. E., Petersen, F. B., Appelbaum, F. R., et al. (1995). Phase II study of busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies. Bone Marrow Transplant., 15, 59-64.